

TR-1: Standard form for notification of major holdings

**1. Issuer Details**

**ISIN**

GB00BMD1Z199

**Issuer Name**

Solvonis Therapeutics PLC

**UK or Non-UK Issuer**

UK

**2. Reason for Notification**

An acquisition or disposal of financial instruments

**3. Details of person subject to the notification obligation**

**Name**

Spreadex LTD

**City of registered office (if applicable)**

St. Albans

**Country of registered office (if applicable)**

United Kingdom

**4. Details of the shareholder**

**Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above**

**City of registered office (if applicable)**

**Country of registered office (if applicable)**

**5. Date on which the threshold was crossed or reached**

02-Apr-2025

**6. Date on which Issuer notified**

03-Apr-2025

**7. Total positions of person(s) subject to the notification obligation**

	% of voting rights attached to shares (total of 8.A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)	Total of both in % (8.A + 8.B)	Total number of voting rights held in issuer
Resulting situation on the date on which threshold was crossed or reached	5.988900	1.132400	7.121300	163500000

Position of previous notification (if applicable)	6.576900	0.392000	6.968900	
---	----------	----------	----------	--

## 8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

### 8A. Voting rights attached to shares

Class/Type of shares ISIN code (if possible)	Number of direct voting rights (DTR5.1)	Number of indirect voting rights (DTR5.2.1)	% of direct voting rights (DTR5.1)	% of indirect voting rights (DTR5.2.1)
GB00BMD1Z199	137500000		5.988900	
Sub Total 8.A	137500000		5.988900%	

### 8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument	Expiration date	Exercise/conversion period	Number of voting rights that may be acquired if the instrument is exercised/converted	% of voting rights
CFD/Spread Bet			26000000	1.132400
Sub Total 8.B1			26000000	1.132400%

### 8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument	Expiration date	Exercise/conversion period	Physical or cash settlement	Number of voting rights	% of voting rights
Sub Total 8.B2					

## 9. Information in relation to the person subject to the notification obligation

1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

Ultimate controlling person	Name of controlled undertaking	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold

## 10. In case of proxy voting

### Name of the proxy holder

### The number and % of voting rights held

### The date until which the voting rights will be held

## 11. Additional Information

Sam Meisel  
01727 895138  
Spreadex is an FCA regulated provider of spread betting and CFD trading. Founded in 1999, Spreadex gives both retail and professional traders the opportunity to trade over 10,000 global markets, including UK small caps. For more information see [www.spreadex.com/financials](http://www.spreadex.com/financials).

## 12. Date of Completion

03-Apr-2025

### 13. Place Of Completion

UK

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@seg.com](mailto:rns@seg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

HOLUNOKRVOUSRAR